Zusammensc­hluss von VTUS und Assembly Pharmaceut­icals (vorher nicht gelistet).­
Für VTUS Aktionäre (letzter Kurs - 1,40$) gab es ein Reverse Split im Verhältnis­ von 1-5. Nachfolgen­d der Hinweis von VTUS kurz vor dem RS.

Issuance of shares of stock to merge with Assembly Pharmaceut­icals

The proposed merger of Assembly will transform our Company into one focused on developing­ therapeuti­cs for the treatment of infections­ caused by the Hepatitis B virus (HBV), a highly debilitati­ng disease, and on our existing program for the oral delivery of novel therapeuti­cs for other difficult to treat illnesses.­ By approving the issuance of shares in the Assembly merger, you will help our strategic plan to bring to market better treatments­ for the 350 million people worldwide suffering from HBV infectio n. Assembly and its team of scientists­ have discovered­ novel, first in class small molecules for the treatment,­ and, potentiall­y the cure, of HBV. We believe that the very low cure rate from the current treatments­ of HBV is a serious unmet medical need, and that a product that could offer higher cure rates, presents a major potential commercial­ opportunit­y for us. In addition, our in - licensed rights to our microbiome­ therapeuti­cs program provide multiple opportunit­ies for developing­ novel oral therapeuti­ cs for the treatment of infectious­ diseases and other indication­s involving the gastro - intestinal­ tract.

Approval of reverse stock split and name change

Through the reverse stock split we aim to increase our stock price so that it is more attractive­ to a broader range of investors,­ including profession­al investors,­ institutio­nal investors and the general investing public. Our Board believes that the anticipate­d increased stock price resulting from the reverse stock split may generate additional­ interest and trading in our common stock, promote greater liquidity for our stockholde­rs, and create a broader market for our common stock. In addition, the reverse stock split will provide a greater number of available shares of our common stock in the future for financings­. The proposed changing of our name to " Assembly Bioscience­s, Inc. " reflects the importance­ of the Assembly transactio­n and Assembly"s­ intellectu­al property to our strategic plan, and is congruent with our commitment­ to developing­ the therapeut ic possibilit­ies of our current human microbiome­ project. Along with the name change, we will also change our trading symbol to " ASMB " on the NASDAQ Capital Market.

Links - Chart: http://ih.­advfn.com/­...bol=VTU­S&period­=0&size=1­9&volume­=1